Clinical Data Update: Recent buzz on social media has centered around Acrivon Therapeutics' latest clinical data release for its cancer drug candidates, ACR-368 and ACR-2316. The Phase 2b trial results for ACR-368 showed a notable 39% response rate in endometrial cancer, sparking lively conversations. Many users are highlighting the potential impact of these results on the company's future.
Stock Movement: Alongside the clinical updates, discussions have noted a significant pre-market stock surge of over 20% following the data announcement. Enthusiasm is high as some speculate on the long-term value of Acrivon’s pipeline, especially with plans to expand trials into Europe. The chatter reflects a mix of optimism and curiosity about upcoming developments.
Note: This discussion summary was generated from an AI condensation of post data.
Acrivon Therapeutics Hedge Fund Activity
We have seen 16 institutional investors add shares of Acrivon Therapeutics stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 682,763 shares (+150057.8%) to their portfolio in Q3 2025, for an estimated $1,235,801
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 382,234 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $691,843
- CITADEL ADVISORS LLC removed 354,193 shares (-18.7%) from their portfolio in Q3 2025, for an estimated $641,089
- HRT FINANCIAL LP removed 145,895 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $264,069
- TWO SIGMA INVESTMENTS, LP added 138,033 shares (+76.2%) to their portfolio in Q3 2025, for an estimated $249,839
- GOLDMAN SACHS GROUP INC removed 120,313 shares (-85.9%) from their portfolio in Q3 2025, for an estimated $217,766
- RENAISSANCE TECHNOLOGIES LLC added 114,105 shares (+22.4%) to their portfolio in Q3 2025, for an estimated $206,530
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Acrivon Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $ACRV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/25/2025
- Oppenheimer issued a "Outperform" rating on 08/14/2025
To track analyst ratings and price targets for Acrivon Therapeutics, check out Quiver Quantitative's $ACRV forecast page.
Acrivon Therapeutics Price Targets
Multiple analysts have issued price targets for $ACRV recently. We have seen 2 analysts offer price targets for $ACRV in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $19.0 on 11/25/2025
- Matthew Biegler from Oppenheimer set a target price of $8.0 on 08/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
